Scientific Advisory Board
John G. Aunins, Ph.D.
John Aunins is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres. He has more than 26 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support, and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq®, and Gardasil®. The Vaqta and Gardasil process teams were awarded with ACS Industrial Biotechnology Awards for innovation, contribution to bioengineering, and societal impact. Dr Aunins is a Fellow of the American Institute for Medical and Biological Engineering and was recently awarded with D.I.C Wang Award for Excellence in Biochemical Engineering. He has authored over 50 articles and book chapters, and has chaired five international conferences in vaccines and bioprocess technology. Dr. Aunins earned his Ph.D. in chemical engineering from MIT, in 1989, under Professor Daniel I.C. Wang. Dr John Aunins is also visiting Professor at ITQB NOVA and member of iBET’s Scientific Advisory Board.
Barry C. Buckland, Ph.D.
Barry Buckland, has been the CEO of BiologicB LLC since 2009. Dr. Buckland serves as a Technical Advisor at Hilleman Laboratories. He served as Head of BioProcess Development at the Protein Sciences Corporation. Dr. Buckland’s career in the pharmal industry includes his leadership of Merck’s bioprocess R&D Group. He is an experienced expert for the Development of Biologics with a special focus on vaccines and Therapeutic proteins. Dr. Buckland was elected as Fellow in the UCL in 1998 and member of US National Academy of Engineering in 1997.
Clive Wood, Ph.D
Clive Wood is Corporate Senior Vice President, Head of Research at Boehringer Ingelheim since 2014. Previously, he was Head of Global Biologics and Senior Vice President at Bayer Healthcare from 2009 to 2014. He is a top senior scientist with extensive experience in research and development of biopharmaceuticals. He has worked in several pharmaceutical companies, and has also close ties with the University. He is Adjunct Professor at the School of Medicine of Boston University and has a long list of patents and publications in high ranking scientific journals
Manuela Pintado, Ph.D.
Manuela Pintado is a Professor at the College of Biotechnology of the Portuguese Catholic University (ESB UCP) since 2005. Since 2017, Manuela Pintado has become the director of CBQF (Chemistry and Biotechnology Center – Portuguese State Associate Laboratory), a ESB UCP research unit and a member of the Research and Internationalization Group of the Portuguese Catholic University (2014-2016). Her research interests include Biotechnology and Biochemistry for the agro-industry.
Jorge Vasconcellos e Sá, MBA, Ph.D.
Vasconcellos e Sá has an MBA from the Peter F. Drucker Graduate School of Management in California, and a PhD in Business Administration, from Columbia University. He was awarded the Jean Monnet Chair. His teaching experience includes the MBA and several executive programs. He has worked as a private consultant, has been a non-executive director or has taught in the executive programmes of multinational companies such as: Coca-Cola, SHELL, Unisys, IBM, Price Waterhouse, Glaxo, BP amongst others.
António Bica, MBA
António Bica is currently Chief Operating Officer at Grupo Medinfar
Rui Frade, Eng
Rui Frade is currently Member of the board at Sumol+Compal.